ESMO shared a post on LinkedIn:
“ESMO TAT Asia 25: In an Opinion piece in the ESMO Daily Reporter, Tony Mok reviews Lung Cancer Clinical Trial data for HER2-, HER3- and TROP-2-targeted Antibody Drug Conjugates (ADCs) as well as other novel targets.
While some of the early results are promising, questions remain around how to optimise ADCs to strike the right balance between efficacy and safety.
The future likely lies in further refining these agents, exploring new targets and incorporating more detailed biomarker analyses to guide treatment decisions.
Title: Target-led treatments for lung cancer – are they moving to the next level?
Author: Tony SK Mok
More posts featuring Tony Mok on OncoDaily.